head and neck cancer
With $8 million in seed funding, Droplet is developing a test for minimal residual disease detection in head and neck cancer, with research ongoing for other promising targets.
Naveris Nabs $33.4M Series A Round Expansion to Further Commercialize Virus-Related Cancer Tests
The new funding brings the total investment in the firm to $51 million, which Naveris will use for commercialization of its NavDx assay.
Bio-Techne Nabs CE Mark for HPV Head and Neck Cancer Test, Completes Namocell Acquisition
The RNAscope ISH Probe High Risk HPV test detects E6/E7 mRNA and is intended to help inform treatment selection in oropharyngeal squamous cell carcinoma patients.
The firm has submitted data to the Centers for Medicare and Medicaid Services' MolDx program to pursue reimbursement.
Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay
The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.